IRulya Therapeutics Inc. (NasdaqCM: IRLA)
Health Care · Biotechnology · US
$39.78
+3.78% today · -88.2% 1Y
IRulya Therapeutics Inc. (NasdaqCM: IRLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $40.46M and employs 38 people.
Over the last twelve months the share price has lost 88.2%, trading between 15.10 and 909.98.
Tweenvest scores IRulya Therapeutics Inc. across four factors: quality 37/100, value 69/100. Its strongest factor is value.
IRLA price history
Key figures
- Market cap
- $40.46M
- Revenue (TTM)
- —
- P/E
- -0.44
- EPS
- -204.79
- Dividend yield
- —
- Beta (5Y)
- 1.79
- 52-week high
- $909.98
- 52-week low
- $15.10
- Avg volume (3M)
- —
- Shares outstanding
- 1.02M
- Employees
- 38
- Next earnings
- —
About IRulya Therapeutics Inc.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
- ISIN
- US22053A3059
- Founded
- 2012
- Listed since
- May 9, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CG Invites Co., Ltd.KOSDAQ: A083790 | $40.73M | ₩708.00 | -6.10% |
| Sprint Bioscience AB (publ)OM: SPRINT | $40.56M | Skr3.87 | +2.38% |
| PanGen Biotech Inc.KOSDAQ: A222110 | $40.55M | ₩4,005.00 | +0.25% |
| Aldeyra Therapeutics, Inc.NasdaqCM: ALDX | $40.51M | $0.67 | -3.29% |
| Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN | $40.16M | $1.98 | +9.39% |
| Cytogen, Inc.KOSDAQ: A217330 | $40.14M | ₩2,320.00 | 0.00% |
| Nano Holdings, Inc.TSE: 4571 | $39.93M | ¥70.00 | +2.94% |
| Alps Group IncNasdaqGM: ALPS | $39.27M | $1.18 | +0.43% |